Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
NCT06374290 · The University of Texas Health Science Center, Houston · PHASE1 · terminated · last registry update 2025-09-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to recruit eligible participants and expiration of study medication.” | – | Registry record, The University of Texas Health Science Center, Houston |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OPRK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-08Phase 3 first posted: Region Skane, naloxone + Placebo (NCT07806565)
- 2026-08-26Results posted on the registry: Yale University, Naltrexone and Bupropion (NB) medication (NCT04605081)
- 2026-08-26Results posted on the registry: Yale University, Naltrexone and Bupropion medication (NCT04599478)
- 2026-08-19Results posted on the registry: Virginia Commonwealth University, Placebo + Auvelity (NCT05976646)
- 2026-08-05Results posted on the registry: Quivive Pharma, Inc., Hydrocodone Bitartrate + Hydrocodone Bitartrate + Doxapram Hydrochloride (NCT06585163)
- 2026-08-04Results posted on the registry: Spaulding Rehabilitation Hospital, Placebo + Oxycodone (NCT03906721)
- 2026-08-03Results posted on the registry: University of Michigan, a drug against OPRK1 (NCT04550715)
- 2026-07-29Also stopped (terminated): Leiden University Medical Center, Narcan 40 MG/ML Nasal Spray + Naloxone Hydrochloride (NCT05338632)
- 2026-07-10Results posted on the registry: Stanford University, Naltrexone + Placebo (NCT04450316)
- 2026-07-10Also stopped (terminated): Stanford University, Naltrexone + Placebo (NCT04450316)
- 2026-07-07Results posted on the registry: University of Missouri-Columbia, a drug against OPRK1 (NCT06238128)
- 2026-07-07Results posted on the registry: University of Kansas Medical Center, Tylenol + Oxycodone (NCT04246697)
- 2026-07-02Results posted on the registry: Joshua A. Lile, Ph.D., Oxycodone (NCT03958474)
- 2026-06-26Phase 3 first posted: Albany Medical College, oral ketamine + oxycodone (NCT07670507)
- 2026-06-15Also stopped (terminated): Wake Forest University Health Sciences, Oxycodone + Acetaminophen (NCT05597878)
- 2026-06-04Results posted on the registry: T. John Winhusen, PhD, Buprenorphine Injection + Buprenorphine Sublingual Product (NCT03918850)
- 2026-06-04Results posted on the registry: University of California, Irvine, Remifentanil + Remifentanil+ Placebo (NCT03066739)
- 2026-06-04Also stopped (terminated): University of California, Irvine, Remifentanil + Remifentanil+ Placebo (NCT03066739)
- 2026-06-03Results posted on the registry: Mayo Clinic, Oxycodone + Ibuprofen (NCT05076110)
- 2026-06-02Results posted on the registry: National Institute on Drug Abuse (NIDA), TRV734 + Oxycodone (NCT04316559)
- 2026-06-02Also stopped (terminated): National Institute on Drug Abuse (NIDA), TRV734 + Oxycodone (NCT04316559)
- 2026-05-19Results posted on the registry: Albert Einstein College of Medicine, naloxone + Morphine sulfate (NCT00678145)
- 2026-05-19Also stopped (terminated): Albert Einstein College of Medicine, naloxone + Morphine sulfate (NCT00678145)
- 2026-05-19Results posted on the registry: Emory University, a drug against OPRK1 (NCT05821699)
- 2026-05-08Also stopped (terminated): Theresa Jacob, PhD, MPH, Buprenorphine/Naloxone (NCT01841931)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision